Table 1 |
||||||||
|
Anti-malarial prescriptions to all patients, presumptive malarial and non-malarial patients. |
||||||||
|
no of prescribed AM* |
% |
no of patients receiving AM |
% |
malarial patients |
% |
non-malarial patients§ |
% |
|
|
|
||||||||
|
total AM* |
73 779 |
100 |
53 391 |
100 |
39 998 |
74.9 |
12 656 |
23.7 |
|
CQ1(total) |
41 103 |
55.7 |
41 103 |
77.0 |
29 452 |
71.7 |
11 058 |
26.9 |
|
Q2(total) |
25 546 |
34.6 |
25 546 |
47.8 |
23 783 |
93.1 |
1 570 |
6.1 |
|
CQ+Q3 |
16 391 |
22.2 |
16 391 |
30.7 |
15 608 |
95.2 |
717 |
4.4 |
|
SP4(total) |
3 785 |
5.1 |
3 785 |
7.1 |
3 275 |
86.5 |
487 |
12.9 |
|
AQ5(total) |
3 335 |
4.5 |
3 335 |
6.2 |
2 845 |
85.3 |
487 |
14.6 |
|
AQ+SP6 |
1 828 |
2.5 |
1 828 |
3.4 |
1 658 |
90.7 |
168 |
9.2 |
|
|
||||||||
|
*AM: Anti-malarials, §patients with unknown clinical diagnosis are excluded. 1CQ (total): total number of chloroquine treatments (CQ prescribed alone and CQ+Q), 2Q (total): total number of quinine treatments (Q prescribed alone and CQ+Q), 3CQ+Q: CQ and Q prescribed together (Q as first treatment and CQ as relay treatment), 4SP (total): total number of sulphadoxine-pyrimethamine treatments, 5AQ (total): total number of amodiaquine treatments, 6AQ+SP: bi-therapy with AQ and SP. |
||||||||
|
Munier et al. Malaria Journal 2009 8:83 doi:10.1186/1475-2875-8-83 |
||||||||
